Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses CTNM in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CTNM in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Carmine Stengone | $655,620 | $0 | $0 | $2,291,640 | $450,739 | $0 | $11,449 | $3,409,448 |
| President and Chief Executive Officer | ||||||||
| Timothy Watkins | 359,501 | 225,000 | 0 | 984,556 | 176,085 | 0 | 18,181 | 1,763,323 |
| Chief Medical Officer and Head of Development | ||||||||
| Peter Slover | 487,487 | 0 | 0 | 840,268 | 238,869 | 0 | 11,279 | 1,577,903 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Carmine Stengone | $3,409,448 | $4,900,039 | — | −1,490,591 |
| Timothy Watkins | 1,763,323 | — | — | — |
| Peter Slover | 1,577,903 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Diego Miralles | RSU | 5,548,320 | — | $2,143,869 |
| Carmine Stengone | Option | 78,164 | 10.81 | — |
| Carmine Stengone | Option | 166,250 | 15.76 | — |
| Carmine Stengone | Option | 300,000 | 9.79 | — |
| Peter Slover | Option | 23,450 | 10.81 | — |
| Peter Slover | Option | 58,334 | 15.76 | — |
| Peter Slover | Option | 110,000 | 9.79 | — |
| Timothy Watkins | Option | 122,778 | 4.5 | — |
The company's compensation program is designed to attract and retain talented executives by providing a competitive base salary and annual incentive bonus based on individual and corporate performance goals, including product development and clinical trial advancement. Long-term incentives are provided through stock options to align executive interests with stockholder value.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Diego MirallesNot independent | $31,889 | — | $197,267 | — | $25,000 | $254,156 |
| Evert SchimmelpenninkIndependent · Board Chair · Compensation | 75,000 | — | 45,035 | — | 0 | 120,035 |
| Todd BradyIndependent · Audit · Compensation (Chair) | 57,500 | — | 45,035 | — | 0 | 102,535 |
| Troy IgnelziIndependent · Audit (Chair) | 55,000 | — | 45,035 | — | 0 | 100,035 |
| Lori M. Lyons-WilliamsIndependent · Audit · Nominating and Corporate Governance | 51,500 | — | 45,035 | — | 0 | 96,535 |
| Olivia WareIndependent · Compensation · Nominating and Corporate Governance | 49,000 | — | 45,035 | — | 0 | 94,035 |
| Sarah BoyceIndependent · Nominating and Corporate Governance (Chair) | 48,000 | — | 45,035 | — | 0 | 93,035 |
| Carmine N. StengoneEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $367,889 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $25,000 |
| Total cost of the board | $392,889 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Contineum Therapeutics | 2025 | Carmine Stengone | $655,620 | $0 | $2,291,640 | $450,739 | $3,409,448 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Carmine Stengone | DEF 14A | 2026-04-30 | 0001628280-26-028881 | Section “Executive Compensation”. As printed: 3,409,448. Filing ↗machine: span 271162–271171 |
| 2 | Section 01, Timothy Watkins | DEF 14A | 2026-04-30 | 0001628280-26-028881 | Section “Executive Compensation”. As printed: 1,763,323. Filing ↗machine: span 282198–282207 |
| 3 | Section 01, Peter Slover | DEF 14A | 2026-04-30 | 0001628280-26-028881 | Section “Executive Compensation”. As printed: 1,577,903. Filing ↗machine: span 277701–277710 |
| 4 | Section 08, Diego Miralles | DEF 14A | 2026-04-30 | 0001628280-26-028881 | Section “Director Compensation”. As printed: 254,156. Filing ↗ |
| 5 | Section 08, Evert Schimmelpennink | DEF 14A | 2026-04-30 | 0001628280-26-028881 | Section “Director Compensation”. As printed: 120,035. Filing ↗ |
| 6 | Section 08, Todd Brady | DEF 14A | 2026-04-30 | 0001628280-26-028881 | Section “Director Compensation”. As printed: 102,535. Filing ↗ |
| 7 | Section 08, Troy Ignelzi | DEF 14A | 2026-04-30 | 0001628280-26-028881 | Section “Director Compensation”. As printed: 100,035. Filing ↗ |
| 8 | Section 08, Lori M. Lyons-Williams | DEF 14A | 2026-04-30 | 0001628280-26-028881 | Section “Director Compensation”. As printed: 96,535. Filing ↗ |
| 9 | Section 08, Olivia Ware | DEF 14A | 2026-04-30 | 0001628280-26-028881 | Section “Director Compensation”. As printed: 94,035. Filing ↗ |
| 10 | Section 08, Sarah Boyce | DEF 14A | 2026-04-30 | 0001628280-26-028881 | Section “Director Compensation”. As printed: 93,035. Filing ↗ |
| 11 | Section 08, Carmine N. Stengone | DEF 14A | 2026-04-30 | 0001628280-26-028881 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 12 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 13 | Section 09b board cost (computed) | Computed | — | computed | Cash 367,889 + equity 0 + all other 25,000 = 392,889, summed across the director compensation table rows.machine: formula: Σ = 392,889 |
| 14 | Contineum Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-30 | 0001628280-26-028881 | CEO total compensation as printed in Contineum Therapeutics's own proxy. As printed: 3,409,448. Filing ↗machine: span 271162–271171 |